We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Infectious Diseases

Maternal Vaccination and Infant Whole-Cell Pertussis Series Synergize for Superior Mucosal Immunity

MedXY Editorial Team•Jan 24, 2026•Infectious Diseases
maternal vaccinationMucosal Immunitypertussis

Highlights

Maternal Tdap-IPV vaccination significantly increases nasal anti-pertussis toxin and anti-B. pertussis IgG in infants at 8 weeks of age, demonstrating effective transplacental transfer to the upper airway mucosa.

Infants receiving the whole-cell pertussis (DTwP) primary vaccine series developed significantly higher mucosal IgG and broader nasal T-cell cytokine responses compared to those receiving the acellular (DTaP) vaccine.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

A Breath of Protection: How a New Nasal Vaccine Could Stop Whooping Cough in its TracksA groundbreaking clinical trial reveals that a novel nasal vaccine, BPZE1, can prevent Bordetella pertussis colonization, offering a potential solution to the transmission gaps in current whooping cough immunization programs.Jan 13, 2026Nirsevimab Outperforms Maternal Vaccination in Reducing Severe RSV Outcomes: Insights from Comparative Real-World EvidenceRecent real-world data from the US and France indicate that while both maternal RSV vaccination and nirsevimab are effective, nirsevimab may offer superior protection against hospitalization and intensive care admission for infants in theirDec 23, 2025Maternal Bivalent Prefusion F RSV Vaccine Significantly Reduces Infant Hospitalisation in UK: Real-World Evidence from a Multicentre StudyA UK-wide multicentre study shows maternal bivalent RSV prefusion F vaccination reduces infant hospitalisation for RSV-associated ALRI by up to 72%, confirming real-world effectiveness matching clinical trials.Oct 4, 2025
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Impact of Maternal Pertussis Vaccination on Infant Immune Responses: Insights from the GaPS Trial in The Gambia
A phase 4 trial in The Gambia finds that maternal Tdap-IPV vaccination is safe and provides early infant protection, but modestly blunts immune responses to whole-cell pertussis vaccines without compromising overall immunogenicity.
Oct 1, 2025